ELAVL1-KO Affects Steroid Synthesis in ACC Cell Line NCI-H295R and Reduces Colony-Forming Abilities

Max Brandau1, Vanessa Kirsch1, Dmitry Chernyakov1

  • 1Klinik für Innere Medizin IV, Landeszentrum für Zell-und Gentherapie, Universitätsklinikum Halle (Saale), 06120 Halle (Saale), Germany.

Insights

Embryonic-Lethal-Abnormal-Vision-Like RNA-Binding Protein 1 (ELAVL1) impacts adrenocortical carcinoma (ACC) progression. ELAVL1 depletion reduces cancer cell proliferation and alters steroidogenesis, suggesting ELAVL1 as a potential therapeutic target for ACC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Adrenocortical carcinoma (ACC) is a rare adrenal gland cancer with limited treatment options for advanced stages.
  • Embryonic-Lethal-Abnormal-Vision-Like RNA-Binding Protein 1 (ELAVL1) expression is linked to poorer patient survival in ACC.
  • Understanding ELAVL1's functional role is crucial for developing novel ACC therapies.

Purpose of the Study:

  • To investigate the functional role of ELAVL1 in adrenocortical carcinoma.
  • To characterize the transcriptomic and steroidogenic consequences of ELAVL1 deficiency in ACC cells.

Main Methods:

  • CRISPR/Cas9 gene editing was used to create ELAVL1 knockout (KO) ACC cell lines (NCI-H295R, HAC15).
  • Next-Generation RNA Sequencing (NGS) analyzed transcriptomic alterations in ELAVL1-deficient cells.
  • Steroid profiling assessed changes in hormone synthesis in KO cells.

Main Results:

  • ELAVL1 depletion significantly altered gene expression, upregulating 3468 and downregulating 3458 genes in NCI-H295R cells.
  • KEGG pathway analysis revealed enrichment in aldosterone biosynthesis and downregulation in "pathways in cancer."
  • ELAVL1-KO cells showed reduced colony formation, increased aldosterone synthesis, and decreased cortisol and androgen production.

Conclusions:

  • ELAVL1 deficiency impairs ACC cell proliferation and alters steroid hormone production.
  • ELAVL1 plays a significant role in ACC pathogenesis and steroidogenesis.
  • ELAVL1 inhibition presents a potential therapeutic strategy for adrenocortical carcinoma.

Related Concept Videos